Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
76.63 USD | +0.86% | +0.54% | +7.25% |
03:18pm | Molten Ventures portfolio firm gets bought by Hologic | AN |
12:56pm | Molten Ventures portfolio firm to buy Endomagnetics for USD310 million | AN |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analyst opinion has improved significantly over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The firm trades with high earnings multiples: 22.96 times its 2024 earnings per share.
- The company's enterprise value to sales, at 4.32 times its current sales, is high.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+7.25% | 17.99B | B+ | ||
+8.69% | 220B | B | ||
+6.69% | 183B | B- | ||
+10.90% | 133B | B- | ||
+25.41% | 107B | A- | ||
-1.33% | 63.05B | A- | ||
+12.72% | 51.74B | B+ | ||
+3.96% | 50.47B | B+ | ||
+0.40% | 40.91B | A | ||
+26.26% | 31.91B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- HOLX Stock
- Ratings Hologic, Inc.